A Modified Electrochemical Sensor Based on N,S-Doped Carbon Dots/Carbon Nanotube-Poly(Amidoamine) Dendrimer Hybrids for Imatinib Mesylate Determination [PDF]
Biosensors, 2023 Imatinib mesylate, an anticancer drug, is prescribed to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. A hybrid nanocomposite of N,S-doped carbon dots/carbon nanotube-poly(amidoamine) dendrimer (N,S-CDs/CNTD) was successfully ...
Maryam Saleh Mohammadnia +3 more
doaj +2 more sources
Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects [PDF]
Clinical and Translational Science, 2022 For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Joo Young Na +7 more
doaj +2 more sources
Green biosynthesis of magnetic iron oxide nanoparticles using Mentha longifolia for imatinib mesylate delivery [PDF]
IET Nanobiotechnology, 2022 In this work, the rapid, facile, and eco‐friendly green process was introduced in the preparation of β‐cyclodextrin/magnetic iron oxide nanoparticles by using the aqueous Mentha longifolia extracts of Mentha longifolia.
Bahareh Naeimipour +4 more
doaj +2 more sources
Imatinib Mesylate and Sirolimus Inhibit Vascular Fibroproliferative Remodeling in Pulmonary Vein Stenosis [PDF]
ChildrenBackground: Pulmonary vein stenosis (PVS) is a progressive disease characterized by neointimal hyperplasia with poor outcomes. Clinical observations show that adjunctive therapy with imatinib mesylate and sirolimus is associated with improved survival ...
Julia Gaal +13 more
doaj +2 more sources
Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1 [PDF]
Clinical Case Reports, 2020 Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.
Ken‐ichi Yasuda +4 more
doaj +2 more sources
Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate [PDF]
Pharmaceutics, 2019 The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6,
Bożena Karolewicz +3 more
doaj +2 more sources
Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes [PDF]
Journal of Bioscience and Applied Research, 2021 Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here evaluating the anticancer of imatinib mesylate and dipyridamole compounds against MDA-MB231 breast cancer cell line in-vitro and the related cell ...
Rania El-Leithy +3 more
doaj +1 more source
Blue nails in chronic myeloid leukemia Is it usual?
National Journal of Physiology, Pharmacy and Pharmacology, 2020 Nail toxicity is an uncommon cutaneous adverse effect of imatinib mesylate. Here, we have described a 45-year-old female, a diagnosed case of Philadelphia positive chronic myeloid leukemia, who was on imatinib mesylate for the past 3 months and developed
Jaydeep Raj Damor +7 more
doaj +1 more source
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience [PDF]
Vojnosanitetski Pregled, 2010 Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).
Ćojbašić Irena +1 more
doaj +1 more source
PLoS ONE, 2014 Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin +7 more
doaj +1 more source